<DOC>
	<DOCNO>NCT00479076</DOCNO>
	<brief_summary>The primary objective study determine recommend phase II dose AVE0005 combination S-1 Japanese cancer patient . The secondary objective study assess safety profile AVE0005 , determine pharmacokinetics AVE0005 , make preliminary assessment antitumor effect .</brief_summary>
	<brief_title>A Phase I Study Intravenous Aflibercept Combination With S-1 Japanese Cancer Patients</brief_title>
	<detailed_description />
	<criteria>Histologically confirm cancer patient without standard care ECOG performance status 0 , 1 , 2 Adequate organ bone marrow function Need major surgery radiation therapy study History hypersensitivity S1 Known dihydropyrimidine dehydrogenase deficiency Uncontrolled hypertension History brain metastasis Ascites require drainage Pregnancy breastfeeding Patients previously treat AVE0005 The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>antineoplastic agent</keyword>
	<keyword>VEGF Trap</keyword>
</DOC>